Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast Cancer

November 19, 2015
Mohammad Jahanzeb, MD

Mohammad Jahanzeb, MD, medical director, Sylvester Comprehensive Cancer Center at Deerfield Beach, talks about the future of treatment for patients with HER2-positive breast cancer with drugs like neratinib and trastuzumab.

Mohammad Jahanzeb, MD, medical director, Sylvester Comprehensive Cancer Center at Deerfield Beach, talks about the future of treatment for patients with HER2-positive breast cancer with drugs like neratinib and trastuzumab. Jahanzeb says that he does not anticipate a head-to-head trial to take place between the two drugs anytime soon.

He says that while the aforementioned trial is currently out of the question, clinicians should use their discretion when dispensing either treatment. Jahanzeb stresses the importance of individualized therapies for patients instead of going with a constant “tried and true” method.